MEMRY ... Stents & more - 500 Beiträge pro Seite

[Techseeker]

Fidelity hat die letzten Monate dazugekauft ...

http://yahoo.marketguide.com/MGI/HoldersReport.asp?target=st…

Immer gut zu sehen, wenn die Grossen bei den Kleinen einsteigen ...

Techs

[Techseeker]

Achja, Memry macht u.a. Medicalprodukte und Produkte aus Shape Memory Alloys (Memory Metalle) und sind z.B. einer der 5 (?) Lieferanten für Stents und Metallkomponten für Boston Scientific.

BSX
http://finance.yahoo.com/q?s=bsx&d=v1

MEMRY
http://finance.yahoo.com/q?s=MRY&d=t

BSX+MEMRY
http://www.google.de/search?hl=de&ie=UTF-8&oe=UTF-8&q=boston…

http://www.google.de/search?q=stents+market+growth+bsx&hl=de…

[Techseeker]

Und hier gibt´s INFO über MEMRY:

http://www.hawkassociates.com/memry/company.htm" target="_blank" rel="nofollow ugc noopener">http://www.hawkassociates.com/memry/company.htm

[Techseeker]

Und hier gibt´s INFO über MEMRY:

http://www.hawkassociates.com/memry/company.htm

[Techseeker]

BETHEL, Conn., Nov. 11 /PRNewswire-FirstCall/ -- Memry Corporation (Amex: MRY - News) announced today that company management will make a presentation to analysts and portfolio managers at The Wall Street Analyst Forum`s Institutional Investor Conference in New York City on Wednesday, November 13th, 2002 at 9:00 am Eastern time.
ADVERTISEMENT


Investors may access a live Internet webcast of the presentation at 9:00 am on November 13th at: http://media.corporate-ir.net/media_files/Event/2002/nov/wsa… The webcast will be archived at this link for approximately 30 days.

[Techseeker]

... und wieder was zu BSX:

Dow Jones Business News
Drug-Coated Stents Seen With 40%-50% Of Euro Market Share
Tuesday November 12, 5:41 am ET


PARIS -(Dow Jones)- Total European market share of drug-coated stents could rise to as much as 40%-50% within the next two to three years from around 5% currently, a cardiologist at the Western Infirmary in Glasgow said Tuesday.
ADVERTISEMENT


The use of drug-coated stents - products that wed potentially clot-busting drugs with the wire mesh tubes that prop open clogged arteries - is now limited by the high cost of the product, Keith Oldroyd said at the SG Cowen Global Health Care Conference in Paris.

Drug-coated products look better than bare metal versions in preventing the re-closing of arteries after surgery, but account for only 5%-6% of the stents now being implanted, he said.

"It`s purely a cost issue - there`s no suggestion so far that there are any negative effects," Oldroyd said. "As soon as a device is available at a reasonable price, the take-up will be enormous."

"If the price difference were just double there`d be no problem with switching, even in the public sector," he said. The extra costs for the stents could be recouped by the savings that stem from not having to re-operate to open up re-clogged arteries, he said.

Oldroyd said he expects the cost of the drug-coated stents to come down in the next 12-18 months as competitors to Johnson & Johnson`s Cypher stent enter the European market.

Boston Scientific Corp. (NYSE:BSX - News) is expected to launch a drug-coated stent onto the European market soon. Oldroyd said he expects the company to launch the product onto the market at a lower price that the J&J rival.

"I expect it to be lower, but how much lower is hard to say," he said.

Oldroyd said the launch of the drug-coated stents has had a serious impact on the cost of bare metal stents. Prices have dropped to around GBP350 a stent from around GBP1,000 since the drug-coated product was launched earlier this year, he said.

Oldroyd said the market share of the drug-coated stents in the U.K. in the next 12-18 months could be anywhere from 20% to 40%, depending on funding decisions by the country`s National Institute for Clinical Excellence.

The regulator is expected to make a decision on reimbursement for drug-coated stents in the third quarter of 2003. NICE will decide which type of patients are eligible to use the stent.

"But in the private sector there has been nearly a complete switch-over to using the Cypher stent," Oldroyd said. "It`s around four times the cost of a bare metal stent, but that doesn`t seem to be putting anybody off."

-By Carey Sargent, Dow Jones Newswires;